Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PAGITANE is an oral small-molecule tablet approved by Eli Lilly in 1953 for an unspecified indication. The exact mechanism of action and therapeutic use are not documented in available data. This is a legacy NDA product with over 70 years of market presence.
Product is in late lifecycle stage with moderate competitive pressure (30%), indicating a wind-down commercial team and limited expansion opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PAGITANE currently has zero linked job openings, reflecting its late-lifecycle stage and minimal active development. Careers on this product focus on defensive commercialization, generic transition planning, and legacy product management rather than growth initiatives.
Worked on PAGITANE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.